Advertisement

Recent advances in the management of fungal infections

  • Jason Sanchez
  • Gary A. Noskin
Part of the Cancer Treatment and Research book series (CTAR)

Abstract

The treatment of cancer has undergone many advances in recent years, leading to significant increases in patient survival. Improvements have come not only in the therapies themselves, but also in our ability to sustain critically ill patients. This, in turn, has allowed more intensive cytotoxic chemotherapies and an increased application of bone marrow transplantation for a broader range of neoplasms. More aggressive chemotherapy regimens have led to more profound immunosuppression and increased risk of infection. Longer survival in more critically ill patients, as well as the relative success of antibacterial therapies, have contributed to a dramatic increase in the incidence of invasive fungal disease among oncology patients. Additional risk factors for fungal infection, common in cancer patients, include the interruption of natural protective barriers by indwelling intravascular catheters, extensive surgical procedures, and chemotherapy-induced disruption of mucosal integrity.

Keywords

Clin Infect Invasive Aspergillosis Positive Blood Culture Invasive Candidiasis Neutropenic Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Anaissie E. Opportunistic mycoses in the immunocompromised host: Experience at a cancer center and review. Clin Infect Dis 1992;14(Suppl. 1):S43–S53.PubMedGoogle Scholar
  2. 2.
    Wingard JR. Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis 1995;20:115–125.PubMedGoogle Scholar
  3. 3.
    Swerdloff JN, Filler SG, Edwards JE. Severe candidal infections in neutropenic patients. Clin Infect Dis 1993;17(Suppl. 2):S457–S467.PubMedGoogle Scholar
  4. 4.
    Slavin MA, Osborne B, Adams R, Levenstein MJ, Schoch HG, Feldman AR, Meyers JD, Bowden RA. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation — A prospective, randomized, double-blind study. J Infect Dis 1995;171:1545–1552.PubMedGoogle Scholar
  5. 5.
    Wey SB, Mori M, Pfaller MA, Soolson RF, Wenzel RP. Hospital-acquired candidemia: The attributable mortality and excess length of stay. Arch Intern Med 1988;148:2642–2645.PubMedCrossRefGoogle Scholar
  6. 6.
    Merz WG. Candida lusitaniae: Frequency of recovery, colonization, infection, and amphotericin B resistance. J Clin Microbiol 1984;20:1194–1195.PubMedGoogle Scholar
  7. 7.
    Voss A, Pfaller MA, Hollis RJ, Rhine-Chalberg J, Doebbeling BN. Investigation of Candida albicans transmission in a surgical intensive care unit cluster with genomic DNA typing methods (abstract no. 1638). In: Program and Abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans). Washington DC: American Society for Microbiology, 1993.Google Scholar
  8. 8.
    Weems JJ. Candida parapsilosis: Epidemiology, pathogenicity, clinical manifestations, and antimicrobial susceptibility. Clin Infect Dis 1992;14:756–766.Google Scholar
  9. 9.
    Beck-Sague CM, Jarvis WR, Banerjee SN, Culver DH, Gaynes RP. Nosocomial fungal infections in U.S. hospitals, 1980-1990 (abstract no. 1129). In: Program and abstracts of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC-American Society for Microbiology, 1990.Google Scholar
  10. 10.
    Komshian SV, Uwaydah, Sobel JD, Crane LR. Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient. Rev Infect Dis 1989;11:379–390.PubMedGoogle Scholar
  11. 11.
    Merz WG, Karp JE, Schron D, Saral R. Increased incidence of fungemia cuased by Candida krusei. J Clin Microbiol 1986;24:581–584.PubMedGoogle Scholar
  12. 12.
    Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991;325:1274–1277.PubMedCrossRefGoogle Scholar
  13. 13.
    Bignardi GE, Savage MA, Coker R, Davis SG. Fluconazole and Candida krusei infections [letter]. J Hosp Infect 1991;18:326–327.PubMedCrossRefGoogle Scholar
  14. 14.
    Mcllroy MA. Failure of fluconazole to suppress fungemia in a patient with fever, neutropenia and typhlitis [letter]. J Infect Dis 1991;163:420–421.Google Scholar
  15. 15.
    Person DA, Laughlin M, Tanner D, Perfect J, Gockerman JP, Hathorn JW. Fluconazole and Candida knisei fungemia [letter], N Engl J Med 1991;325:1315.Google Scholar
  16. 16.
    Diamond RD, Lyman CA, Wysong DR. Disparate effects of interferon and tumor necrosis factor in early neutrophil respiratory burst and fungicidal responses to Candida albicans hyphae in vitro. J Clin Invest 1991;87:711–720.PubMedGoogle Scholar
  17. 17.
    Lyman CA, Simons ER, Melnick DA, et al. Induction of signal transduction in human neutrophils by Candida albicans hyphae: The role of pertussis toxin-sensitive guanosine triphosphate-binding proteins. J Infect Dis 1988;158:1056–1064.PubMedGoogle Scholar
  18. 18.
    Fleischmann J, Lehrer RI. Phagocytic mechanism in host response. In: Howard DH, ed. Fungi Pathogenic for Humans and Animals, Part B2. New York: Marcel Dekker, 1985, pp. 123–149.Google Scholar
  19. 19.
    Brown AE. Overview of fungal infections in cancer patients. Semin Oncol 1990;17(Suppl. 6):2–5.Google Scholar
  20. 20.
    Odds FC, Schmid J, Soll DR. Epidemiology of Candida infections in AIDS. In: Vanden Bossche H, MacKenzie DWR, Cauwenbergh G, Van Cutsem J, Drouhet E, Dupont B, eds. Mycoses in AIDS patients. New York: Plenum Press, 1990, pp. 67–74.Google Scholar
  21. 21.
    Lecciones JA, Lee JW, Navarro EE, et al. Vascular catheter-associated fungemia in patients with cancer: Analysis of 155 episodes. Clin Infect Dis 1992;14:875–883.PubMedGoogle Scholar
  22. 22.
    Isenberg HD, Tucci V, Cintron F, Singer C, Weinstein GS, Tyras DH. Single-source outbreak of Candida tropicalis complicating coronary bypass surgery. J Clin Microbiol 1989;27:2426–2428.PubMedGoogle Scholar
  23. 23.
    Martino P, Girmenia C, Venditti M, et al. Candida colonization and systemic infection in neutropenic patients: A retrospective study. Cancer 1989;64:2030–2034.PubMedCrossRefGoogle Scholar
  24. 24.
    Cole GT, Halawa AA, Anaissie EJ. The role of the gastrointestinal tract in hematogenous candidiasis: From the laboratory to the bedside. Clin Infect Dis 1996;22(Suppl. 2):s73–s88.PubMedGoogle Scholar
  25. 25.
    Krause W, Matheis H, Wulf K. Fungemia and funguria after oral administration of Candida albicans. Lancet 1969;l:598–599.CrossRefGoogle Scholar
  26. 26.
    Stone HH, Kolb LD, Currie CA, et al. Candida sepsis: Pathogenesis and principles of treatment. Ann Surg, 1974:697–711.Google Scholar
  27. 27.
    Wade JC. Epidemiology of Candida infection. In: Bodey GP, ed. Candidiasis: Pathogenesis, Diagnosis, and Treatment, 2nd ed. New York: Raven Press, 1993, p. 85.Google Scholar
  28. 28.
    McDonald G, Sharma P, Hackman R, Meyers J, Thomas ED. Infectious esophagitis in immunocompromised patients after marrow transplantation. Gastroenterology 1985, 88:1111–1117.PubMedGoogle Scholar
  29. 29.
    Pfaller MA. Epidemiology and control of fungal infections. Clin Infect Dis 1994;19(Suppl. 1):S8–S13.PubMedGoogle Scholar
  30. 30.
    Edwards JE. Candida species. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases, 4th ed. New York: Churchill Livingstone, 1995, pp. 2289–2305.Google Scholar
  31. 31.
    Walsh, TJ, Lee JW, Roilides E, Pizzo PA. Recent progress and current problems in management of invasive fungal infections in patients with neoplastic deseases. Curr Opin Oncol 1992;4:647–655.PubMedCrossRefGoogle Scholar
  32. 32.
    Bodey GP. Disseminated candidiases in neutropenic patients. Int J Infect Dis 1997;l(Suppl. 1):S2–S6.Google Scholar
  33. 33.
    Flynn PM, Shenep JL, Crawford R, Hughes WT. Use of abdominal computed tomography for identifying disseminated fungal infection in pediatric cancer patients. Clin Infect Dis 1995;20:964–970.PubMedGoogle Scholar
  34. 34.
    Meunier F, Aoun M, Bitar N. Candidemia in immunocompromised patients. Clin Infect Dis 1992;14(Suppl. l):S120–S125.PubMedGoogle Scholar
  35. 35.
    Lecciones J, Witebsky F, Marshall D, Gress J, Pizzo P, Walsh TJ. Catheter-associated fungemia in cancer patients: Characteristics and clinical outcome (abstract no. 68). In: Program and Abstracts of the 29th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC: American Society for Microbiology, 1989, p. 112.Google Scholar
  36. 36.
    Edwards JE. Invasive Candida infection. N Engl J Med 1991;324:1060–1062.PubMedCrossRefGoogle Scholar
  37. 37.
    Young RC, Bennett JE, Geelhoed GW, et al. Fungemia with compromised host resistance. A study of 70 cases. Ann Intern Med 1974;80:605–612.PubMedGoogle Scholar
  38. 38.
    Polak A. 5-Fluorocytosine and combinations. Ann Biol Clin (Paris) 1987;45:669–672.Google Scholar
  39. 39.
    Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994;331:1325–1330.PubMedCrossRefGoogle Scholar
  40. 40.
    Stevens DA. Overview of amphotericin B colloidal dispersion (amphocil). J Infect 1994;28(Suppl. 1):S45–S49.CrossRefGoogle Scholar
  41. 41.
    Eppes SC, Troutman JL, Gutman LT. Outcome of treatment of candidemia in children whose central catheters were removed or retained. Pediatr Infect Dis J 1989;8:99–104.PubMedCrossRefGoogle Scholar
  42. 42.
    Dato VM, DAjani AS. Candidemia in children with central venous catheters: Role of catheter removal and amphotericin B therapy. Pediatr Infect Dis J 1990;9:309–314.PubMedCrossRefGoogle Scholar
  43. 43.
    Bennett JE. Aspergillus species. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases, 4th ed. New York: Churchill Livingstone, 1995, pp. 2306–2310.Google Scholar
  44. 44.
    Talbot GH, Huang A, Provencher M. Invasive Aspergillus rhinosinusitis in patients with acute leukemia. Rev Infect Dis 1991;13:219–232.PubMedGoogle Scholar
  45. 45.
    Peterson DE, Schimpff SC. Aspergillus sinusitis in neutropenic patients with cancer: A review. Biomed Pharmacother 1989;43:307–312.PubMedCrossRefGoogle Scholar
  46. 46.
    Young RC, Bennett JE, Vogel CL, et al. Aspergillosis. The spectrum of the disease in 98 patients. Medicine 1970;49:147–173.PubMedCrossRefGoogle Scholar
  47. 47.
    Meyer RD, Young LS, Armstrong D, et ai. Aspergillosis complicating neoplastic disease. Am J Med 1973;54:6.PubMedCrossRefGoogle Scholar
  48. 48.
    Pagano L, Ricci P, Nosari A, Tonso A, Buelli M, Montillo M, Cudillo L, et al. Fatal haemoptysis in pulmonary filamentous mycosis: An underevaluated cause of death in patients with acute leukaemia in haematological complete remission. A retrospective study and review of the literature. Br J Haematol 1995;89:500–505.PubMedGoogle Scholar
  49. 49.
    Wallace TM Jr., Sais GJ, Frank I, Gefter WB, Aronchick JM, Wallace TM. Pulmonary aspergillosis in patients with AIDS. Chest 1994;105:37–44.CrossRefGoogle Scholar
  50. 50.
    Young RC, Jennings A, Bennett Je. Species identification of invasive aspergillosis in man. Am J Clin Pathol 1972;58:554–557.PubMedGoogle Scholar
  51. 51.
    Green WR, Font RI, Zimmerman LE. Aspergillosis of the orbit. Report of ten cases and review of the literature. Arch Ophthalmol 1969:82:302–313.PubMedGoogle Scholar
  52. 52.
    Allo MD, Miller J, Townsend T, Tan C. Primary cutaneous aspergillosis associated with Hickman intravenous catheters. N Engl J Med1987;317:1105–1108.PubMedCrossRefGoogle Scholar
  53. 53.
    Kusne S, Torre-Cisneros J, Manez R, et al. Factors associated with invasive lung aspergillosis and the significance of positive Aspergillus cultures after liver transplantation. J Infect Dis 1992;166:1379–1383.PubMedGoogle Scholar
  54. 54.
    Boon AP, O’Brien D, Adams DH. 10 year review of invasive aspergillosis detected at necropsy. J Clin Pathol 1991;44:452–454.PubMedCrossRefGoogle Scholar
  55. 55.
    von Eiff M, Roos N, Schulten R, Hesse M, Zuhlsdorf M, van de Loo J. Pulmonary aspergillosis: Early diagnosis improves survival. Respiration 1995;62:341–347.CrossRefGoogle Scholar
  56. 56.
    Hruban RH, Meziane MA, Zerhouni EA, Wheeler PS, Dumler JS, Hutchins GM. Radiologie-pathologic correlation of the CT halo sign in invasive pulmonary aspergillosis. J Comput Assist Tomogr 1987;11:534–536.PubMedCrossRefGoogle Scholar
  57. 57.
    Faggian G, Livi U, Bortolotti U, et al. Intraconazole therapy for acute invasive pulmonary aspergillosis in heart transplantation. Transplant Proc1989;21:2506–2507.PubMedGoogle Scholar
  58. 58.
    Denning DW, Tucker RM, Hanson LH, et al. Treatment of invasive aspergillosis with itraconazole. Am J Med 1989;86:791–800.PubMedCrossRefGoogle Scholar
  59. 59.
    Berthier M, Palmieri O, Lylyk P, et al. Rhino-orbital phycomycosis complicated by cerebral abscess. Neuroradiology 1982;22:221–224.PubMedCrossRefGoogle Scholar
  60. 60.
    Meyers BR, Wormser G, Hirschman SZ, et al. Rhinocerebral mucormycosis. Premortem diagnosis and therapy. Arch Intern Med 1979;139:557–560.PubMedCrossRefGoogle Scholar
  61. 61.
    Maniglia AJ, Mintz DH, Novak S. Cephalic phycomycosis: A report of eight cases. Laryngoscope 1982;92:755–760.PubMedCrossRefGoogle Scholar
  62. 62.
    Abedi E, Sismanis A, Choi K, et al. Twenty five years’ experience treating cerebro-rhino-orbital mucormycosis. Laryngoscope 1984;94:1060–1062.PubMedGoogle Scholar
  63. 63.
    Lehrer RI, Howard DH, Sypherd PS, et al. Mucormycosis. Ann Intern Med 1980;93:93–108.Google Scholar
  64. 64.
    Kolbeck PC, Makhoul RG, Bollinger RR, et al. Widely disseminated Cunninghamella mucormycosis in an adult renal transplant patient: A case report and review of the literature. Am J Clin Pathol 1985;83:747–753.PubMedGoogle Scholar
  65. 65.
    Perfect JR, Schell WA. The new fungal opportunists are coming. Clin Infect Dis 1996;22(Suppl. 2):S112–S118.PubMedGoogle Scholar
  66. 66.
    D’Antonio D, Mazzoni A, Iacone A, Violante B, Capuani MA, Schioppa F, Romano F. Emergence of fluconazole-resistant strains of Blastoschizomyces capitatus causing nosocomial infections in cancer patients. J Clin Microbiol 1996;34:753–755.PubMedGoogle Scholar
  67. 67.
    Strausbaugh LJ, Sewell DL, Ward TT, Pfaller MA, Heitzman T, Tjoelker R. High frequency of yeast carriage on hands of hospital personnel. J Clin Microbiol 1994;32:2299–2300.PubMedGoogle Scholar
  68. 68.
    Vartivarian SE, Anaissie EJ, Bidey GP. Emerging fungal pathogens in immunocopromised patients: Classification, diagnosis, and management. Clin Infect Dis 1993;17(Suppl. 2):S487–S491.PubMedGoogle Scholar
  69. 69.
    Walsh TJ, Melcher GP, Rinaldi MG, et al. Trichosporon beigelii, an emerging pathogen resistant to amphotericin B. J Clin Microbiol 1990;28:1616–1622.PubMedGoogle Scholar
  70. 70.
    Hoy J, Hsu K-C, Rolston K, Hopfer RL, Luna M, Bodey GP. Trichosporon beigelii infection: A review. Rev Infect Dis 1986:8:959–967.PubMedGoogle Scholar
  71. 71.
    Martino P, Venditti M, Micozzi A, Morace G, Polonelli L, Mantovani MP, Petti MC, Burgio VL, Santini C, Serra P, Mandelli F. Blastoschizomyces capitatus: An emerging cause of invasive fungal disease in leukemia patients. Rev Infect Dis 1990;12:570–582.PubMedGoogle Scholar
  72. 72.
    McManus EJ, Bozdech MJ, Jones JM. Role of the latex agglutination test for cryptococcal antigen in diagnosing disseminated infections with Trichosporon beigelii. J Infect Dis 1985;1167–1169.Google Scholar
  73. 73.
    Hazen KC. New and emerging yeast pathogens. Clin Microbiol Rev 1995;8:462–478.PubMedGoogle Scholar
  74. 74.
    Kiehn TE, Gorey E, Brown AE, Edwards FF, Armstrong D. Sepsis due to Rhodotorula related to use of indwelling central venous catheters. Clin Infect Dis 1992;14:841–846.PubMedGoogle Scholar
  75. 75.
    Martino P, Gastaldi R, Raccah R, Girmenia C. Clinical patterns of Fusarium infections in immunocompromised patients. J Infect 1994;28(Suppl. 1):S7–S15.CrossRefGoogle Scholar
  76. 76.
    Morrison VA, Haake RJ, Weisdorf D J. Non-Candida fungal infections after bone marrow transplantation: Risk factors and outcome. Am J Med1994;96:497–503.PubMedCrossRefGoogle Scholar
  77. 77.
    Merz WG, Karp JE, Hoagland M, Jett-Gogeen M, Junkins JM, Hood AF. Diagnosis and successful treatment of fusariosis in the compromised host. J Infect Dis1988;158:1046–1055.PubMedGoogle Scholar
  78. 78.
    Anaissie E, Kantarjian H, Ro J, et al. The emerging role of Fusarium infections in patients with cancer. Medicine (Baltimore) 1988;67:77–83.PubMedCrossRefGoogle Scholar
  79. 79.
    Fotergill AW. Identification of dematiaceous fungi and their role in human disease. Clin Infect Dis 1996;22(Suppl. 2):S179–S184.Google Scholar

Copyright information

© Kluwer Academic Publishers, Boston 1998

Authors and Affiliations

  • Jason Sanchez
  • Gary A. Noskin

There are no affiliations available

Personalised recommendations